Introduction The heterogeneity of symptoms and complex etiology of depression pose a
significant challenge to the personalization of treatment. Meanwhile, the current application …

Background Pharmacogenomic testing has recently become scalable and available to guide
the treatment of major depressive disorder (MDD). The objective of the current meta-analysis …

Objective: Pharmacogenomic testing has become scalable and available to the general
public. Pharmacogenomics has shown promise for predicting antidepressant response and …

The degree of agreement between four commercial pharmacogenetic-based decision
support tools (DSTs) was examined in five outpatients with major depressive disorder and at …

After the development of “classical” tricyclic antidepressants and monoamine oxidase
inhibitors, numerous other classes of antidepressant drugs have been introduced onto the …

Objective: During the past decades, increasing efforts have been invested in studies to
unravel the influence of genetic factors on antipsychotic (AP) dosage, treatment response …

Antidepressants demonstrate modest response rates in the treatment of major depressive
disorder (MDD). Despite previous genome-wide association studies (GWAS) of …

Background: Personalized medicine is a model in which a patient's unique clinical, genetic,
and environmental characteristics are the basis for treatment and prevention. Aim, method …

Antidepressants are commonly prescribed medications in the United States, and there is
increasing interest in individualizing treatment selection for more than 20 US Food and Drug …

Objectives: More than 40 drugs are available to treat affective disorders. Individual selection
of the optimal drug and dose is required to attain the highest possible efficacy and …